Due to recently filed counterclaims in patent lawsuit by
BICO,
The products concerned are expected to account for approximately 1-2 percent of the Group's estimated revenues in 2022 and therefore this is non-material for the Group. BICO remains steadfastly committed to evolving the future of health. As the world's leading bio convergence company, we look forward to continuing to set the trends in the bio convergence space and collaborating with our industry peers to work toward solving the major health challenges we face as a society.
Background
CELLINK filed a complaint for a declaratory judgment inJune 2021 to theU.S. District Court inDelaware about non-infringement of certain ofOrganovo's patents in order to strengthen our market position and freedom to operate.-
In July, 2021,
Organovo , filed a patent infringement action againstCELLINK in theU.S. District Court in theWestern District ofTexas , asserting that a singleCELLINK product family infringes fourU.S. patents.Organovo's Texas Court Action was later, inDecember 2021 , transferred to theDelaware Court and both cases will from now on be tried by theDelaware court. -
The so-called counterclaims filed by
Organovo inJanuary 2022 refers to the transferred claims from theTexas Court. We strongly oppose the counter claim, and our standpoint is clear:Organovo's patent claims at issue are invalid, not infringed, or both.
For further information, please contact:
Phone (US): +1 (857) 332 2138
Phone (
Email: gd@bico.com
Phone (
Email: lb@bico.com
This information was submitted for publication, through the agency of the contact persons set out above, on
About BICO
Founded in 2016, BICO (formerly
The company has a focus on developing technologies that will advance Health 4.0 Next Generation Core Industry Ecosystems that enable tissue engineering, diagnostics, multiomics, and cell line development. BICO's technologies enable researchers in the life sciences to culture cells in 3D, perform high-throughput drug screening and print human tissues and organs for the medical, pharmaceutical, and cosmetic industries. We create the future of health.
The Group's instruments in the field amounts to 25,000, including all the top 20 pharmaceutical companies, are being used in more than 65 countries, and have been cited in more than 9,500 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com
https://news.cision.com/bico-group/r/statement-from-bico-regarding-counterclaims-in-patent-lawsuit-by-organovo-against-group-company-cell,c3484476
https://mb.cision.com/Main/14960/3484476/1519191.pdf
(c) 2022 Cision. All rights reserved., source